| Literature DB >> 30513813 |
Karolina A Chodkowska1, Anna Ciecierska2, Kinga Majchrzak3, Piotr Ostaszewski4, Tomasz Sadkowski5.
Abstract
Gamma-oryzanol (GO) is a popular supplement for performance horses, dogs, and humans. Previous studies indicated that GO supplementation decreases creatine kinase activity and lactate level after exercise and may affect oxidative stress in Thoroughbred horses. GO may change genes expression in equine satellite cells (ESC). The purpose of this study was to evaluate the effect of GO on miRNA, gene expression, oxidative stress, and cell damage and viability in differentiating ESC pretreated with hydrogen peroxide (H₂O₂). ESCs were obtained from a young horse's skeletal muscle. ESCs were pre-incubated with GO (24 h) and then exposed to H₂O₂ for one hour. For the microRNA and gene expression assessment, the microarray technique was used. Identified miRNAs and genes were validated using real time-quantitative polymerase chain reaction. Several tests related to cell viability, cell damage, and oxidative stress were performed. The microarray analysis revealed differences in 17 miRNAs and 202 genes between GO-treated and control ESC. The tests related to apoptosis, cell viability, and oxidative stress showed that GO affects these processes to varying degrees. Our results suggest that GO can change miRNA and gene expression and may impact the processes involved in tissue repairing after an injury.Entities:
Keywords: apoptosis; equine satellite cells; gamma-oryzanol; hydrogen peroxide; miRNA; muscle injuries; oxidative stress; target genes
Mesh:
Substances:
Year: 2018 PMID: 30513813 PMCID: PMC6316332 DOI: 10.3390/nu10121871
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Experimental design: (A) control group (ESCs incubated with hydrogen peroxide) and (B) GO-treated group incubated with hydrogen peroxide.
Real-time qPCR primers
|
| |||||
|
|
|
|
| ||
| 1 | miR-133a | UUUGGUCCCCUUCAACCAGCUG | 10 s/95 °C and 60 s/60 °C | ||
| 2 | miR-345 | GCUGACUCCUAGUCCAGUGCUC | 10 s/95 °C and 60 s/60 °C | ||
| 3 | miR-675 | UGGUGCGGAGAGGGCCCACAGUG | 10 s/95 °C and 60 s/60 °C | ||
|
| |||||
|
|
|
|
|
|
|
| 1 |
| CCACCTCCTGCAGAACAAAAG | GGGTCTTGGTAAAGGCTCATT | 15 s/60 °C | 326 |
| 2 |
| CTCCAGACCACCAACAACTC | CCCCTGGGACTTCACCTTAT | 15 s/62 °C | 261 |
| 3 |
| TCCTCCTCAGTCATAGAGCAAT | CTCTGTTTCACTCCCCTTTCTT | 15 s/60 °C | 340 |
| 4 |
| AGAGTTGGAGGAGAGCAGAT | TGGAGGGTAAACTGGCTGAT | 15 s/60 °C | 209 |
| 5 |
| GCTCGCAGAAAGAAGAAGGT | GGTGCTTTTCCATCCACAGA | 15 s/60 °C | 329 |
| 6 |
| CGAGGCTACAGTATCCCTGA | CTTTCACTGTTGAGGGCTGT | 15 s/60 °C | 257 |
| 7 |
| GTTTGTGATGGGCGTGAACC | GTCTTCTGGGTGGCAGTGAT | 15 s/60 °C | 198 |
Note: (A) indiates miRNA; (B) indicates mRNA.
MiRNAs differentially expressed in GO-incubated equine satellite cells exposed to H2O2, compared to control.
| No. | miRNA Name | FC (GO vs. ctrl) | Log FC (GO vs. ctrl) | Regulation (GO vs. ctrl) | miRbase Accession No |
|---|---|---|---|---|---|
| 1 | eca-miR-188-5p | 2.18 | 1.13 | up | MIMAT0013198 |
| 2 | eca-miR-212 | 1.68 | 0.75 | up | MIMAT0013030 |
| 3 | eca-miR-685_v14.0 | 1.61 | 0.68 | up | MIMAT0012904 |
| 4 | eca-miR-133a | 1.33 | 0.41 | up | MIMAT0012997 |
| 5 | eca-miR-208b | 1.30 | 0.38 | up | MIMAT0012900 |
| 6 | eca-miR-675 | −46.67 | −5.54 | down | MIMAT0013053 |
| 7 | eca-miR-10a | −43.24 | −5.43 | down | MIMAT0013019 |
| 8 | eca-miR-502-5p | −41.35 | −5.37 | down | MIMAT0013225 |
| 9 | eca-miR-708 | −40.90 | −5.35 | down | MIMAT0012993 |
| 10 | eca-miR-345-5p | −33.19 | −5.05 | down | MIMAT0013138 |
| 11 | eca-miR-142-3p | −28.34 | −4.82 | down | MIMAT0013023 |
| 12 | eca-miR-324-3p | −1.75 | −0.81 | down | MIMAT0013034 |
| 13 | eca-miR-199b-5p | −1.65 | −0.72 | down | MIMAT0013780 |
| 14 | eca-miR-92a | −1.47 | −0.56 | down | MIMAT0013089 |
| 15 | eca-miR-222 | −1.45 | −0.53 | down | MIMAT0013204 |
| 16 | eca-miR-874 | −1.42 | −0.50 | down | MIMAT0013069 |
| 17 | eca-miR-29c | −1.31 | −0.39 | down | MIMAT0012964 |
FDR ≤ 0.05, FC ≥ 1.3, n = 8, FC-Fold Change, FDR-False Discovery Rate.
Real-Time qPCR validation of differentially expressed genes and miRNAs.
| No. | GO vs. Control | Fold Change | |
|---|---|---|---|
| 1 |
| 11.78 | 0.003 |
| 2 |
| −6.37 | 0.005 |
| 3 |
| −6.32 | 0.007 |
| 4 |
| 120.89 | 0.008 |
| 5 |
| 2.78 | 0.020 |
| 6 | miR-133a | 1.71 | 0.023 |
| 7 | miR-345 | −5.33 | 0.001 |
| 8 | miR-675 | 1.39 | 0.038 |
Figure 2miRNAs and their differentially expressed target genes (DET) in combination with processes that may be associated with muscle tissue during injury and regeneration.
Figure 3Effect of GO on cell viability measured by SYTOX Red Cell Dead assay. Statistical analysis was performed using the one-way ANOVA (p < 0.05). H2O2 denotes cells without GO treatment, exposed to H2O2; H2O2+GO denotes cells treated with GO and exposed to H2O2.
Figure 4Effect of GO on (A) oxidative stress, (B) lipid peroxidation, and (C) total antioxidant capacity in equine satellite cell cultures exposed to hydrogen peroxide. (A) Each value is the mean ± standard error of the results from three different plates (n = 3). Statistical analysis was performed using the unpaired t-test (two tailed) (p < 0.05); (B) Each value is the mean ± standard error (n = 6). Statistical analysis was performed using the unpaired t-test (two tailed) (p < 0.05); (C) Data are expressed as means ± standard (n = 6). Statistical analysis was performed using the unpaired t-test (two tailed) (p < 0.05).
Figure 5Qualitative flow cytometry assay for mitochondrial depolarization. Data are expressed as mean ± standard error (n = 3). Statistical analysis was performed using the one-way ANOVA (p < 0.05). H2O2 denotes cells without GO treatment, exposed to H2O2; H2O2+GO denotes cells treated with GO and exposed to H2O2.; Q1 population: % of aggregates; Q2 population: % of monomers + aggregates; Q3 population: % of monomers; Q4 population: % of monomers (−)/aggregates (−).
Identified signaling pathways and related DET.
| Pathway | Genes | FDR | |
|---|---|---|---|
| AMP-activated protein kinase (AMPK) signaling pathway |
| 1.00 × 10−2 | 9.50 |
| Proteoglycan in cancer |
| 2.80 × 10−2 | 24.0 |
| Endocytosis |
| 4.50 × 10−2 | 36.0 |
| Fatty acid metabolism Peroxisome proliferator-activated receptor |
| 6.30 × 10−2 | 47.0 |
| (PPAR) signaling pathway |
| 8.70 × 10−2 | 58.0 |
Figure 6Relationships between DET and miRNAs, based on Pathway Studio Web Mammal. Genes are marked with red clouds and blue clouds for up- and down-regulation, respectively.
DET and related processes together with corresponding miRNAs.
| No. | Target Gene Symbol | Gene Description | Biological Processes | Fold Change (Microarray) | Related Identified miRNAs |
|---|---|---|---|---|---|
| 1. |
| Acyl-CoA Synthetase Long-Chain Family Member 3 | Lipid biosynthesis and fatty acid degradation; Anabolic role in energy metabolism; Cell proliferation; Cell differentiation | −1.13 | miR-142↓ miR-222↓ |
| 2. |
| ADAM metallopeptidase with thrombospondin type 1 motif | Proteolysis; Protein processing; Inflammation | 1.18 |
|
| 3. |
| BCDIN3 domain containing RNA Methyltransferase | Methylation; miRNA metabolic process | −1.13 | miR-29↓ miR-502↓ |
| 4. |
| CCR4-NOT transcription complex, subunit 2 | Inflammation; Cytoplasmic deadenylation; DNA damage response; Regulation of stem cell population maintenance | −1.12 | |
| 5. |
| Cylindromatosis (Turban Tumor Syndrome) | Cell survival, proliferation, and differentiation; Innate immunity; Negative regulation of nf-kappa B import into nucleus | 1.35 | miR-133↑ miR-212↑ |
| 6. |
| ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 | Embryonic cell differentiation; Cytokine-induced cachexia; Cell growth and proliferation; Regulation of translation; Regulation of stem cell population maintenance | −1.23 | |
| 7. |
| G-rich RNA sequence binding factor 1 | RNA processing; Cell proliferation; Protein synthesis: Apoptosis | −1.23 | |
| 8. |
| Insulin like growth factor 1 receptor | Apoptosis; Cell growth, differentiation and survival control; Immune response; Regulation of MAPK cascade; Oxidative stress | 1.28 | miR-133↑ |
| 9. |
| Insulin-like growth factor 2 | Growth factor activity; Striated muscle cell differentiation; Positive regulation of glycogen Biosynthetic process; Satellite cell proliferation | 1.52 | miR-133↑ |
| 10. |
| Minichromosome Maintenance Complex Binding Protein | A key regulator of pre-replication complex | −1.21 | |
| 11. |
| Nuclear receptor subfamily 2, group F, member 2 | Muscle organ development: Cell migration; Cell proliferation; Inflammation | 1.11 | miR-212↑ |
| 12. |
| RAB11A A member RAS oncogene family | Metabolic process; Inflammation; Marker for myopathies | −1.17 | miR-142↓ |
| 13. |
| RNA Binding Protein with Multiple Splicing | Response to oxidative stress; Heart, and gastrointestinal smooth Muscle development | −1.24 | miR-199↓ |
| 14. |
| Rho-associated, coiled-coil containing protein kinase 1 | Regulation of smooth muscle contraction; Regulation of actin filament-based process; Apoptotic process; Loss of muscle protein | −1.21 |
|
| 15. |
| Sterile Alpha Motif Domain Containing 4A | Cell junction; Modulates the activities of the mechanistic target of rapamycin complex 1; Regulates muscle/fat volume; Highly muscle-specific gene; (potential marker in dmd) | 1.23 |
|
| 16. |
| Stearoyl-CoA Desaturase | Fatty acid biosynthesis; Biosynthesis of membrane phospholipids, cholesterol esters, and triglycerides; Cholesterol esterification; Muscle metabolism | −1.54 | miR-199↓ |
| 17. |
| Small EDRK-Rich Factor 2 | Marker of spinal and muscular atrophy; Muscle cachexia, muscle loss; Cell proliferation; Oxidative stress; Apoptosis | 1.12 |
|
| 18. |
| SET Domain Containing 6 | Protein binding; Cell differentiation; Apoptosis | 1.21 | |
| 19. |
| Sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) | Muscle organ/cell development; Cardiac muscle tissue development; Muscle dystrophy; Cell apoptosis | 1.44 |
|
| 20. |
| Small ArfGAP 1 | Endocytosis; Cell differentiation; Apoptosis; Cell migration; Cell proliferation | −1.10 | miR-10a↓ |
| 21. |
| Vascular Endothelial Zinc Finger 1 | Normal and abnormal cellular Proliferation and differentiation; DNA methylation | 1.34 |
|
| 22. |
| Zinc Finger SWIM-Type Containing 6 | Metal ion binding; Dysostosis | 1.20 | miR-208↑ |
miRNAs in bold have the opposite expression change to corresponding DET. The arrows indicate the direction of expression change: ↓ and ↑ for down- and up-regulation, respectively.
Figure 7Relationships between differentially expressed genes, selected miRNAs and metabolic processes.
Figure 8Number of DEG assigned to biological processes.
Primary metabolism processes and DEG.
| No. | Process | Number of Genes | Genes |
|---|---|---|---|
| 1 | Nucleobase-containing compound metabolic process (GO:0006139) | 21 |
|
| 2 | Carbohydrates metabolic process (GO:0005975) | 3 |
|
| 3 | Cellular amino acid metabolic process (GO: 0006520) | 4 |
|
| 4 | Lipid metabolic process (GO:0006629) | 3 |
|
| 5 | Protein metabolic process (GO:0019538) | 20 |
|
| 6 | Tricarboxylic acid cycle (GO:0006099) | 1 |
|
Figure 9Potential role of GO-induced miRNAs and selected target genes in muscle regeneration process.